Abstract
A new derivative of octreotide SDZ 219-387 [PnAO-(D)Phe1-octreotide] was synthesized, which binds specifically and with high affinity to somatostatin receptors in vitro (pK= 9.79±0.16). This new somatostatin analogue chelates technetium-99m under mild labelling conditions in good yields. The resulting [99mTc]SDZ 219–387 was stable up to 6 h after labelling and could be isolated in a pure radiochemical and chemical form by high-performance liquid chromatographic purification. The intravenous administration of purified [99mTc]SDZ 219–387 revealed that the radioligand was rapidly cleared from circulation, and tumour uptake of 0.38% ID/g was observed at 1.5 h post injection. [99mTc]SDZ 219–387 specifically interacted with somatostatin binding sites on the tumour. However, the radioligand is highly lipophilic and excreted mainly through the hepatobiliary system. As a consequence, [99mTc]SDZ 219–387 exhibits increased background activity and therefore is not appropriate for the in vivo visualization of somatostatin receptor-positive tumours and/or their metastases in the abdomen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brazeau P, Vale W Burgus R. Hypothalamic peptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–79.
Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495–1563.
Wängberg B, Nilsson O, Theodorsson E, Dahlstroem A, Ahlman H. The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumor cells Br J Cancer 1991; 64: 23–28.
Lamberts SWJ. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogues in the treatment of human pituitary tumors. Endocr Rev 1988; 9: 417–436.
Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogues in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450–482.
Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–1140.
Weckbecker G, Liu R, Tolcsvai L, Bruns C. Antiproliferative effects of octreotide (SMS 201–995) on ZR-75–1 human breast cancer cells in vivo and in vitro. Cancer Res 1992; 52: 4973–4978.
Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC, Klijn JG, Visser TJ, Docter R, Lamberts S. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabelling, purification, biologic activity and in vivo application in animals. J Nucl Med 1990; 31: 1501–1509.
Krenning EP, Breeman WA, Bakker WH, Koper JW, Kooij PP, Ansema L, Lamberts SWJ, Reubi JC. Localization of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1989; 1: 242–244.
Lamberts SWJ, Hofland LJ, vanKoetsveld PM, Reubi JC, Bruining HA, Bakker WH, Krenning EP. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization and therapy. J Clin Endocr Metab 1990; 7: 566–574.
Bakker WH, Krenning EP, Reubi JC, Breeman WAP, Selyono-Han B, deJong M, Kooij PPM, Bruns C, van Hagen PM, Marbach P, Visser TJ, Pless J, Lamberts SWJ. In vivo application of [111In-DTPA-DPhe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991; 49: 1593–1601.
Bruns C, Stolz B, Albert R, Marbach P, Pless P. OctreoScan 111 for imaging of a somatostatin receptor positive islet cell tumor in rat. Horm Metab Res 1993; Suppl 27(5):5–11.
Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, deJong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, van Hagen PM, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with indium-111-DTPA-D-phe-l-octreotide in man: metabolism, dosimetry and comparison with iodine- 123-tyr-3-octreotide. J Nucl Med 1992; 33: 652–658.
Smith-Jones P, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, Mäcke H. [67/68Ga]-[Desferroxamine B-succinyl-(D)Phe1]-octreotide a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis, radiolabelling, in vitro and preliminary in vivo studies. J Nucl Med 1994; 35: 317–325.
Clark MJ, Podbielski L. Medical diagnostic imaging with complexes of 99mTc. Coord Chem Rev 1987; 78: 253–331.
Deutsch E, Libson K. Recent advances in technetium chemistry: Bridging inorganic chemistry and nuclear medicine. Comments Inorg Chem 1984; 3: 83–103.
Kowalsky RJ, Perry RJ. Radiopharmaceuticals in nuclear medicine practice. Norwalk, Conn.: Appleton & Lange; 1987:68.
Bruns Ch. Died MM, Palacios J. Identification and characterization of somatostatin receptors in neonatal rat long bones. Biochem J 1990; 256: 39–44.
Troutner DE, Volkert WA, Hoffman TJ, Holmes RA. A neutral lipophilic complex of 99mTc with a multidentate amine oxime. Int JAppl Radiat Isot 1984; 35: 467–470.
Volkert WA, Hoffman TJ, Seger RM, Troutner DE, Holmes RA. 99mTc-propylene amine oxime (99mTc-PnAO); a potential brain radiopharmaceutical. Eur J Nucl Med 1984; 9: 511–516.
Volkert WA, McKenzie EH, Hoffman TJ, Troutner DE, Holmes RA. The behavior of neutral amine oxime chelates labelled with Tc at tracer level. Int J Nucl Med Biol 1984; 11: 243–246.
Hajri A, Bruns C, Marbach P, Aprahamian M, Longnecker DS, Damgé C. Inhibition of the growth of transplanted rat pancreatic acinar carcinoma with octreotide. Eur J Cancer 1991; 27: 1247–1252.
Longnecker DS, Rebuck BD, Vager JD Jr, Liljia HS, Siegmund B. Pancreatic carcinoma in azaserine treated rats: induction, classification and dietary modulation of incidence. Cancer 1981; 47: 1562–1572.
Esteban JM, Schlom J, Gansow OA, Atcher RW, Brechbiel MW, Simpson DE, Colcher D. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1987; 28: 861–870.
Mukkala VM, Mikola H, Hemmilae I. The synthesis and use of activated N-benzyl derivatives of diethylenetriaminetetraacetic acids: alternative reagents for labelling of antibodies with metal ions. Anal Biochem 1989; 176: 319–325.
Parker D. Tumor targeting. Chem Br 1990; 26: 942–945.
Koch P. Synthese and Evaluation bifunktioneller 99mTc-Chelatoren und ihr Einsatz in der Diagnose von Tumoren mittels monoklonaler Antikörper. PhD Thesis, Faculty of Natural Sciences, Basel University, Basel, Switzerland, 1992.
Deutsch E, Heineman WR, Zodda JP, Gilbert TW, Williams CC. Preparation of “no-carrier-added” technetium-99m complexes: determination of the total technetium content of generator eluents. Int J Appl Radiat Isot 1982; 33: 843–848.
Neirinckx RD, Canning LIZ, Piper IM, Nowotnik DP, Pickett RD, Holmes RA, Volkert WA, Forster AM, Weisner PS, Marriott JA, Chaplin SB. Technetium-99m d,l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 1987; 28: 191–202.
Koch P, Macke HR. Ein 99mTc-markiertes Biotinkonjugat in einer Tumor-“Pretargeting”-Methode mit monoklonalen Antikoerper. Angew Chemie (Int Ed) 1992; 31: 1501–1509.
Thakur ML, Eshbach J, McDevitt MR, Wilder S, Damjanov JE. A Tc-99m and In-111 labelled somatostatin analogue: preparation and preliminary evaluation as a receptor specific agent [abstract No. 111]. J Nucl Med 1992; 33 (Suppl): 851.
Author information
Authors and Affiliations
Additional information
Correspondence to: T. Maina
Rights and permissions
About this article
Cite this article
Maina, T., Stolz, B., Albert, R. et al. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219–387) labelled with technetium-99m. Eur J Nucl Med 21, 437–444 (1994). https://doi.org/10.1007/BF00171420
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00171420